Trial
NCT05576896
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Northwestern University
Collaborators
National Cancer Institute (NCI)
Condition
Stage IV Colorectal Cancer Positive for BRAF V600E Mutation
Intervention
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
Why stopped
The study was closed due to accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-12